新辅助临床试验为癌症药物发现提供了一个机会之窗。
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery.
机构信息
The neoAdjuvant Research Group to Evaluate Therapeutics (TARGET), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Immunotherapy and Novel TargEt Research Across Clinical Teams (INTERACT), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Nat Med. 2022 Apr;28(4):626-629. doi: 10.1038/s41591-022-01681-x.
Abstract
Window-of-opportunity trials, during which patients receive short-duration pre-surgical therapies, provide a platform for understanding the therapies’ mechanisms of action, but will require a paradigm shift in trial design, specimen collection and analysis.
摘要
机会之窗试验，在此期间患者接受短疗程术前治疗，为了解治疗的作用机制提供了一个平台，但需要在试验设计、标本采集和分析方面进行范式转变。
相似文献
1
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery.
Nat Med. 2022 Apr;28(4):626-629. doi: 10.1038/s41591-022-01681-x.
2
Drug development: neoadjuvant opportunities in breast cancer.
Am Soc Clin Oncol Educ Book. 2013:73-9. doi: 10.14694/EdBook_AM.2013.33.73.
3
Cracking open window of opportunity trials.
J Clin Oncol. 2012 Jul 20;30(21):2573-5. doi: 10.1200/JCO.2012.42.3293. Epub 2012 May 7.
4
Neoadjuvant breast cancer therapy and drug development.
Clin Adv Hematol Oncol. 2015 Nov;13(11):755-61.
5
Neoadjuvant trials could speed up drug approvals.
J Natl Cancer Inst. 2014 Mar;106(3):dju072. doi: 10.1093/jnci/dju072. Epub 2014 Mar 7.
6
Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Clin Adv Hematol Oncol. 2016 Jul;14(7):520-30.
7
Preoperative chemotherapy for breast cancer.
Clin Adv Hematol Oncol. 2004 Apr;2(4):212, 215.
8
Neoadjuvant Trials in ER Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
Cancer Discov. 2017 Jun;7(6):561-574. doi: 10.1158/2159-8290.CD-17-0228. Epub 2017 May 11.
9
Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?
Minerva Chir. 2015 Jun;70(3):181-93. Epub 2015 Mar 4.
10
Chemotherapy: Neoadjuvant trial design: time for a brave new world?
Nat Rev Clin Oncol. 2010 Jul;7(7):359-60. doi: 10.1038/nrclinonc.2010.85.
引用本文的文献
1
Improving outcomes of patients with pancreatic cancer.
Nat Rev Clin Oncol. 2025 May 6. doi: 10.1038/s41571-025-01019-9.
2
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.
Nat Rev Clin Oncol. 2024 Dec;21(12):839-851. doi: 10.1038/s41571-024-00943-6. Epub 2024 Sep 24.
3
Multiplexed immunohistochemical analysis of the immune microenvironment of biliary tract cancers pre- & post-neoadjuvant chemotherapy: case series.
Ann Transl Med. 2024 Aug 1;12(4):78. doi: 10.21037/atm-23-1928. Epub 2024 Jun 5.
4
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.
Nat Rev Cancer. 2024 Jul;24(7):498-512. doi: 10.1038/s41568-024-00705-7. Epub 2024 Jun 12.
5
Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.
PLoS Comput Biol. 2024 May 3;20(5):e1012088. doi: 10.1371/journal.pcbi.1012088. eCollection 2024 May.
6
Embracing cancer complexity: Hallmarks of systemic disease.
Cell. 2024 Mar 28;187(7):1589-1616. doi: 10.1016/j.cell.2024.02.009.
7
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. doi: 10.1038/s41571-024-00868-0. Epub 2024 Feb 29.
8
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.
Oncogene. 2023 Oct;42(44):3252-3259. doi: 10.1038/s41388-023-02835-y. Epub 2023 Sep 21.
9
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. Epub 2023 Sep 6.
10
The complementarity of DDR, nucleic acids and anti-tumour immunity.
Nature. 2023 Jul;619(7970):475-486. doi: 10.1038/s41586-023-06069-6. Epub 2023 Jul 19.
Zotero 插件